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Introduction: Intrathecal synthesis of immunoglobulins can often 
be observed in patients with multiple sclerosis (MS) and clinically 
isolated syndrome (CIS) and the amount of intrathecal immuno-
globulin synthesis in an individual patient remains relatively stable 
over time. We could previously show an association between the 
IgG index and genetic variants located around the immunoglobulin 
heavy chain locus (IGHC) on chromosome 14 using a genome 
wide association study (GWAS). The variants corresponded to dif-
ferent allotypes that code for structurally distinct immunoglobulin 
heavy chains. The aim of this study was to confirm the previously 
described association by genotyping the single nucleotide poly-
morphism (SNP) rs74093865, which is in strong linkage disequi-
librium (r2 0.9) with the lead SNP rs10136766 from our previous 
study and to further investigate the effect of this genetic variant on 
intrathecal synthesis of IgA and IgM.
Methods: DNA samples from 785 MS or CIS patients with avail-
able data on intrathecal immunoglobulin synthesis, who were not 
part of our previous study, were obtained and genotyped for the 
rs74093865 using a TaqMan SNP genotyping assay . The associa-
tion between rs74093865 and rank transformed IgG, IgM and IgA 
indices was tested using linear regression with adjustments made 
for sex, age, assay plate, time points of lumbar puncture and DNA 
sampling.
Results: rs74093865 was significantly associated with indices for 
IgG, IgM and IgA in patients with MS and CIS. In accordance 
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with our previous findings, the A allele, which corresponds to the 
IGHC Gm21* allotype, correlated with higher IgG index (p=2E-
13). Interestingly, lower IgM and IgA indices were seen in patients 
carrying the A allele of rs74093865 (p=3E-7 and p=5E-4 for IgM 
and IgA indices, respectively).
Conclusion: The results of this study confirm the association of a 
genetic variant located around the immunoglobulin heavy chain 
locus with intrathecal immunoglobulin synthesis. Interestingly the 
Gm21* allotype seems to be associated with higher intrathecal 
IgG synthesis and lower intrathecal IgA and IgM synthesis.
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